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Abstract
Objectives: To analyse the effects of rosiglitazone administered at different times on neointimal
formation in hypercholesterolemic rabbits following vascular injury.
Methods:  Thirty-nine rabbits on a hypercholesterolemic diet were included. The animals
underwent balloon catheter injury to the right iliac artery on day 14. They were divided into three
groups as follows: control group, 13 rabbits without rosiglitazone; group I, 13 rabbits treated with
rosiglitazone (3 mg/Kg body weight/day) for 28 days after the vascular injury; and group II, 13
rabbits treated with rosiglitazone (3 mg/Kg body weight/day) during all the experiment (42 days).
Histological analysis was done by an experienced pathologist who was unaware of the rosiglitazone
treatment. Histomorphometric parameters were performed by calculation of the luminal and
intimal layer area, and intima/media layer area ratio (the area of the intimal layer divided by the area
of the medial layer).
Results: Intimal area was significantly lower in group II vs. CG (p = 0.024) and group I (p = 0.006).
Luminal layer area was higher in group II vs. CG (p < 0.0001) and group I (p < 0.0001). Intima/media
layer area ratio was equal between CG and group I. Intima/media layer ratio area was significantly
lower in group II vs. control group (p < 0.021) and group I (p < 0.003). There was a significant
reduction of 65% and 71% in intima/media layer area ratio in group II vs. control group and group
I, respectively.
Conclusion:  Pretreatment with rosiglitazone in hypercholesterolemic rabbits submitted to
vascular injury significantly reduces neointimal formation.
Introduction
Peroxisome proliferator-activated receptor-γ (PPARγ) has
been shown to be expressed in many of the cells that play
a role in the response to vascular injury and to modulate
the actions that are thought to initiate neointimal (NI)
growth, including inflammation [1-4]. Neointimal forma-
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tion is an important structural change in the vessel wall
that leads to restenosis after angioplasty or stenting [5-8].
Thiazolidinediones consist of a family of synthetic com-
pounds that acts as high-affinity ligands for PPARγ and
were originally developed to facilitate glucose control in
patients with type 2 diabetes. In addition, they have a
direct impact on vascular cells and reduce circulating fac-
tors that are associated with atherosclerosis [9]. In a recent
meta-analysis of randomized controlled trials there was
evidence that thiazolidinedione therapy in patients
undergoing coronary stent implantation may be associ-
ated with less in-stent restenosis and repeated revasculari-
zation [10-12]. Three different thiazolidinediones,
rosiglitazone, pioglitazone, and troglitazone, have been
shown to prevent balloon-injured rat carotid arteries [9].
Rosiglitazone can reduce the NI formation and macro-
phage content in a mouse injury model [1] and in hyper-
cholesterolemic rabbits [2]. These effects were
independent of glycemic control or changes in lipid con-
centrations [13]. In the present study we analyse the
effects of rosiglitazone (RGZ) on neointimal formation
administered at different times in hypercholesterolemic
rabbits following vascular injury.
Methods
Animals
Thirty-nine white adult male rabbits (New Zealand),
weighing 2.474 ± 348 Kg, were utilized for this experi-
ment. Animals were handled in compliance with the
Guiding Principles in the Care and Use of Animals. Proto-
col approval was obtained from the Pontifical Catholic
University Animal Research Committee. During first 14
days the animals were fed a hypercholesterolemic diet
(1% cholesterol-Sigma-Aldrich®). Subsequently, they
were changed to a 0.5% cholesterol diet until sacrifice (42
days). The animals were divided into three groups as fol-
lows: control group (CG) 13 rabbits without RGZ; group
I, 13 rabbits treated with RGZ from the fifteenth day (after
the vascular injury) until sacrifice; and group II, 13 rabbits
treated with RGZ during the entire experiment (42 days).
Rosiglitazone was administered by oral gavage (3 mg/Kg
body weight/day).
Vascular injury
The rabbits underwent balloon catheter (20 × 3 mm/5
atm/5 min) injury of the right iliac artery on the four-
teenth day of the experiment. Anesthesia was induced
with ketamine (Vetanarcol®-König – 3,5 mg/Kg) and intra-
muscular xylazine (Coopazine®-Coopers – 5 mg/Kg).
After the procedure the animals received intramuscular
analgesics for 3 days (25 mg/day of flunixin – Banamine®
– Schering-Plough) and intramuscular antibiotics for 4
days (100 mg/day of oxitetraciclin – TormicinaP®-
Toruga). The rabbits were sacrificed by a lethal barbiturate
dose on day 42 and their aorta and iliac arteries were
removed for immunohistochemical and histological anal-
ysis.
Quantitative histopathology
Histological analysis was performed by an experienced
pathologist (LN) unaware of the RGZ treatment. The anal-
yses was done with a microscope attached to the Image
Pro-plus®  4.5 Software (Media Cybernetics Inc. Silver
Spring, MD. USA). Histomorphometric parameters were
performed by calculation of the luminal and intimal layer
area, and intima/media layer area ratio (the area of the
intimal layer divided by the area of the medial layer)
according to the method described by Phillips et al [1].
The quantification of total collagen was made by the Sir-
ius red polarization method [14]. Atherosclerotic lesions
were analysed and classified according to Virmani et al
[15].
Immunohistochemistry
Tissue preparation and immunohistological techniques
were performed according to the manufacturer's instruc-
tions included in the kits (Dako Corporation, Carpinteria,
Calif). Sections were stained for macrophage cells using
primary monoclonal antibody RAM-11(Dako®, Carpinte-
ria, CA), and for alpha-actin smooth muscle cells with pri-
mary polyclonal antibody HHF-35 (Dako®, Carpinteria,
CA). For quantitative immunocytochemical comparisons
of macrophage content or smooth muscle cell content in
intimal area, sections were computed and scored in 2 cat-
egories based on less than or more than 50% of cells in the
balloon injury area.
Blood chemistry
Blood samples were obtained on first day of the experi-
ment, immediately before balloon catheter injury, and
immediately before sacrifice by cardiac puncture. Clinical
laboratory assessment included fasting serum glucose,
total cholesterol (TC), high-density lipoprotein choles-
terol (HDL-C), and triglycerides (TGC). Measurements
were done using an automated system (Abbott Architect
ci8200; Abbott Laboratories, Abbott Park, Il).
Statistical analysis
The calculation of sample size was done based on the
study of Wang Zhao-hui, Luo Feng and Liu Xiao-mei [16].
The ratio between the intimal layer and the media layer
was considered to be the main variable of interest. In
order to detect a minimum difference of 0.15 between
groups averages, with a significance level of 5% and power
of the test of 80%, the minimum number of animals in
each group of the study was defined as 12. Categorical var-
iables were expressed as percentages and continuous vari-
ables were expressed as mean ± SD and medians. Data
were compared using Anova one-way. The normality ofThrombosis Journal 2008, 6:12 http://www.thrombosisjournal.com/content/6/1/12
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the samples was tested by using Shapiro-Wilk tests. For
non-normal samples, the Kruskal-Wallis and Mann-Whit-
ney non parametric tests were used to compare the
groups. Fisher's exact test was used for qualitative or cate-
gorical variables. Statistical significance was indicated by
a value of p < 0.05. Analyses were performed using SPSS
version 14.0 (SPSS, Inc., Chicago, Illinois).
Results
Metabolic and lipid profiles
The rabbit's weight did not differ between groups (data
not shown). Baselineglucose, total cholesterol, HDL-cho-
lesterol and triglycerides levels were equal in all groups
before initiation of the diet. On day 14, two weeks after
feeding, fasting glucose levels were higher in CG and
group I. At the time of sacrifice glucose levels did not differ
between groups. A graded elevation in TC and TGC levels
was observed from the initial phase through the vascular
lesion until sacrifice without significant differences
between groups. A graded elevation in HDL-C was
observed in all three groups. Higher levels of HDL-C were
observed in group II versus CG and group I at the time of
vascular injury and sacrifice (Table 1).
Histomorphometry
Intimal area was significantly lower in group II vs. CG (p
= 0.024) and group I (p = 0.006). Luminal layer area was
higher in group II vs. CG (p < 0.0001) and group I (p <
0.0001). There was a significant reduction of 65% and
71% in intima/media layer area ratio (IMR) in group II vs.
CG (p = 0.021) and vs. group I (p = 0.003), respectively.
Intima/media layer area ratio was equal between CG and
group I. (Table 2). (Figures 1 and 2). According to the his-
tological analysis proposed by Virmani et al, none of the
criteria from1 trough 9 were found in group II, therefore
the comparisons were only made between CG and group
I. Neointimal growth, xanthomatous macrophages, prote-
oglican matrix, the presence and the thickness of fibrous
cap, and the presence of calcification did not differ
between CG and group I. There was no deposit of collagen
into intimal or medial layers in group II, nor were there
differences in the extent of collagen deposition between
CG and group I. (Table 3).
Immunohistochemistry
There was no significant difference in macrophage and
smooth muscle cell content in the intimal layer between
CG and group I (data not show). Group II did not present
any intimal cell markers.
Discussion
Prevention of restenosis after balloon coronary angi-
oplasty or stent implantation with the use of local and sys-
temic therapy is a challenging issue in interventional
cardiology [4,17-20]. Osborne et al [21] showed that a
short term model of hypercholesterolemia (two to four
weeks) prevents extremely high cholesterol values and for-
mation of advanced atherosclerotic plaques. Nevertheless,
the arteries isolated from animals fed a cholesterol-
enriched diet developed defects in endothelium-depend-
ent relaxation in both large vessels as well as coronary
resistance vessels [22]. These effects could be, in part,
responsible for the restenosis after balloon angioplasty.
Thiazolidinediones have immunomodulatory and anti-
proliferative effects, independent of their actions in meta-
bolic control and are expressed in most cell types of the
vascular wall as in atherosclerotic lesions, where they can
affect atherogenic process [23-30]. To investigate the
effects of a PPARγ ligand (rosiglitazone) on atherogenesis
in an animal model, we used rabbits with six-fold
increased cholesterol levels at the time of vascular injury
and fourteen-fold increased levels at the time of euthana-
sia. This animal model was based on previous studies
where rabbits develop hypercholesterolemia rapidly after
excessive cholesterol feeding [2,3,22,24]. The metabolic
effects of high cholesterol-containing diet on rabbits were
Table 1: Metabolic and lipid profiles (mean ± SD)
CG Group I Group II P value
Baseline TC (mg/dl) 58.62 ± 25.08 50.77 ± 18.39 43.54 ± 14.82 NS
HDL-C (mg/dl) 24.23 ± 5.31 23.1 ± 6.12 22.69 ± 6.26 NS *
TGC (mg/dl) 79.62 ± 26.64 91.15 ± 32.71 79.85 ± 34.31 NS *
Glucose (mg/dl) 121.38 ± 17.43 120.77 ± 19.07 117.92 ± 11.44 NS
Vascular injury TC (mg/dl) 524.38 ± 258.94 431.77 ± 197.38 318.46 ± 212.86 NS
HDL-C (mg/dl) 32.46 ± 19.66 28.77 ± 6.15 50.69 ± 21.91 NS *
TGC (mg/dl) 72.77 ± 34.95 71.54 ± 46.54 86.92 ± 56.34 NS *
Glucose (mg/dl) 250.23 ± 93.02 274.46 ± 58.45 166.62 ± 38.2 0.001
Sacrifice TC (mg/dl) 852.46 ± 308.48 702.62 ± 261.53 593.54 ± 219,86 NS
HDL-C (mg/dl) 42.62 ± 38.23 25.08 ± 13.93 69.08 ± 19.7 0,001 *
TGC (mg/dl) 126.77 ± 85.66 398.08 ± 509.76 277.31 ± 248.14 NS *
Glucose (mg/dl) 212.85 ± 73.71 210.92 ± 72.99 233.85 ± 89.65 NS
NS – non significant.
* Kruskal-WallisThrombosis Journal 2008, 6:12 http://www.thrombosisjournal.com/content/6/1/12
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extensively explained in our previous study [31]. Rosigli-
tazone was used at different times for each group. Group
II not only did not present atherosclerotic lesions but also
did not show any deposit of collagen or macrophage and
smooth muscle cell markers in their intimal layer. The
most significant findings were identified in the higher
luminal area and the lower intimal area in which rabbits
were treated with RGZ before vascular injury. Further-
more, in CG and group I intense reparative response
occurred, with exuberant neointimal formation and
reduction of luminal area. In addition, immunohisto-
chemical analysis demonstrated a reduced macrophage
and smooth muscle cell recruitment into the vascular arte-
rial wall when RGZ was used two weeks before catheter
balloon injury. Rosiglitazone did not exert anti-athero-
sclerotic activity when administered after vascular injury,
however, a lesser density of macrophages in the media
layer was observed in the animals of group I. We cannot
rule out that these effects were due to chance, as our eval-
uation period was short. These findings suggest a possible
Representative histological sections demonstrating neointimal formation – Orcein Staining Figure 1
Representative histological sections demonstrating neointimal formation – Orcein Staining.Panel A: Control 
group. Panel B: Group I. Panel C: Group II. NI represents neointima.
Quantification of intima/media layer area ratio; and total intimal layer area Figure 2
Quantification of intima/media layer area ratio; and total intimal layer area.Thrombosis Journal 2008, 6:12 http://www.thrombosisjournal.com/content/6/1/12
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protective effect of this drug against neointimal prolifera-
tion and remodeling responsible for restenosis after a bal-
loon angioplasty. This is the first study to show the effects
of a PPARγ ligand on vascular injury at different times and
to document the benefits of pre-treatment with RGZ in
hypercholesterolemic rabbits. Nevertheless, this drug has
been the focus of extensive discussion in recent publica-
tions [32-37]. Nissen and Wolski [32] published a meta-
analysis showing a significant increase in the risk of myo-
cardial infarction and an increase in cardiovascular death
of borderline significance in patients with diabetes receiv-
ing RGZ. Singh et al [33] also published a meta-analysis
showing a significantly increased risk of myocardial inf-
arction and heart failure among patients with impaired
glucose tolerance or type 2 diabetes using rosiglitazone for
at least 12 months, with no significantly increased risk of
cardiovascular mortality. Lipscombe et al [34], in a nested
case-control analysis of a retrospective cohort study,
found that in diabetes patients with an age of 66 years or
older, RGZ treatment was associated with an increased
risk of congestive heart failure, acute myocardial infarc-
tion, and mortality when compared with other combina-
tion oral hypoglycemic agent treatments. The mechanism
for the apparent increase in myocardial infarction and
death from cardiovascular causes associated with RGZ
remains uncertain. In the PERISCOPE randomized con-
trolled trial [37], using coronary intravascular ultrasonog-
raphy, the authors found a significantly lower rate of
progression of coronary atherosclerosis in patients treated
with pioglitazone when compared with glimiperide.
However, it is not possible to extend the positive or nega-
tive benefit of one drug to another in the same class. In the
next three years, we hope that the final results of the stud-
ies RECORD and BARI-2D [38], specifically evaluating
cardiovascular effects of RGZ, will provide useful insights.
Conclusion
The results of our study indicate that when rosiglitazone is
administered in hypercholesterolemic rabbits before, but
Table 2: Quantitative histopathological analysis
Area Group Mean DP Minimum Maximum P
Intimal area CG 320340.22 392880.74 14720.20 1512612.11 0.024
GI 282659.14 346471.14 14500.40 1361362.80 0.006
GII 83115.01 65440.66 16187.50 269226.60
Luminal area CG 458711.01 363013.82 1853.54 1773080.00 <0.0001
GI 556450.31 330540.15 3274.59 1486461.00 <0.0001
GII 861255.24 303153.71 222741.70 1586336.00
IMR CG 0.50 0.41 0.04 1.13 0.021
GI 0.59 0.36 0.08 1.36 0.003
GII 0.18 0.14 0.03 0.49
IMR represents intima/media area ratio. Area was estimated in square micrometer.
Table 3: Qualitative histopathology between CG and Group I
Presence CG Group I p value
Intimal thickening (%) No 30.76 15.38 > 0.05
Yes 69.23 84.61 > 0.05
Isolated Xanthomamacrophages (%) No 30.76 15.38 > 0.05
Yes 69.23 84.61 > 0.05
Agregate Xanthomamacrophages (%) No 38.46 15.38 > 0.05
Yes 61.53 84.61 > 0.05
Lipid drops of proteoglican matrix (%) No 38.46 15.38 > 0.05
Yes 61.53 84.61 > 0.05
Lipid lakes of proteoglican matrix (%) No 38.46 30.76 > 0.05
Yes 61.53 69.23 > 0.05
Thin fibrous cap atheroma (%) No 84.61 92.30 > 0.05
Yes 15.38 7.69 > 0.05
Calcified nodule (%) No 53.84 15.38 > 0.05
Yes 46.15 84.61 > 0.05
Calcification (%) No 92.30 76.92 > 0.05
Yes 7.69 23.07 > 0.05
Collagen Type I (mean ± sd) 880.9 ± 436.5 264.5 ± 104.04 0.29
Collagen Type III (mean ± sd) 680.5 ± 267.54 312.24 ± 98.89 0.41
No represents less than 50% of cells in the balloon injury area. Yes represents more than 50% of cells in the balloon injury area.Thrombosis Journal 2008, 6:12 http://www.thrombosisjournal.com/content/6/1/12
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not after, undergoing vascular injury, there is significantly
reduced neointimal formation.
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